Satsuma Pharmaceuticals EBITDA vs. Number Of Shares Shorted
| STSADelisted Stock | USD 1.10 0.01 0.90% |
For Satsuma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Satsuma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Satsuma Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Satsuma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Satsuma Pharmaceuticals over time as well as its relative position and ranking within its peers.
Satsuma |
Satsuma Pharmaceuticals Number Of Shares Shorted vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Satsuma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Satsuma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Satsuma Pharmaceuticals is rated below average in ebitda category among its peers. It is rated below average in number of shares shorted category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Satsuma Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Satsuma Number Of Shares Shorted vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Satsuma Pharmaceuticals |
| = | (58.31 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Satsuma Pharmaceuticals |
| = | 130.12 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Satsuma Number Of Shares Shorted Comparison
Satsuma Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Satsuma Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Satsuma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Satsuma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Satsuma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Satsuma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Satsuma Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.
Satsuma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Satsuma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Satsuma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Satsuma Pharmaceuticals' important profitability drivers and their relationship over time.
Use Satsuma Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Satsuma Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Satsuma Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Satsuma Pharmaceuticals Pair Trading
Satsuma Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Satsuma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Satsuma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Satsuma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Satsuma Pharmaceuticals to buy it.
The correlation of Satsuma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Satsuma Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Satsuma Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Satsuma Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Satsuma Pharmaceuticals position
In addition to having Satsuma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Defense Thematic Idea Now
Defense
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Defense theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Defense Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |